In recent years, growing studies have been unmasking significant neuroprotective properties of SGLT2 inhibitors in different CNS-related disorders, such as Alzheimer’s disease, Huntington's disease, Parkinson's disease, as well as cerebral ischemia, major depression, and epilepsy (Borikar et al. 2024; El-Sahar et al. 2020; Muhammad et al. 2021; Rizzo et al. 2022). The gene discussed is SLC5A2; the disease is early-onset autosomal dominant Alzheimer disease.